Attovia Therapeutics, Inc.

General form for quarterly reports under Section 13 or 15(d)

Results of Operations and Financial Condition

Beneficial ownership report for a passive holder of more than 5% (Schedule 13G)

Beneficial ownership report for a holder of more than 5% (Schedule 13D)

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement with Pricing Information

Amended Initial Registration Statement

Notice of Effectiveness

Certification of approval for listing and registration on a national securities exchange

Amended Initial Registration Statement

Registration of Securities on Exchange

Registration (IPO) statement under Securities Act of 1933

Draft registration statement (confidential submission) (amendment)

Draft registration statement (confidential submission) (amendment)

WALSH COLIN

GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS GROUP INC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS EMP ONSHORE INVESTMENTS, L.P.; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP

GOLDMAN SACHS GROUP INC

GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS GROUP INC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS EMP ONSHORE INVESTMENTS, L.P.; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP

WALSH COLIN

venBio Global Strategic Fund IV, L.P.

KROIN DAVID; Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.

Redmile Group, LLC; Green Jeremy; Redmile Biopharma Investments III, L.P.

Sanofi

Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc.

You Angie

FHMLS XI, L.P.; Frazier Life Sciences XI, L.P.; FHMLS XI, L.L.C.

GOLD MITCHELL

Odrowaz Zaneta

Veiby Petter

Chen Hubert

WALSH COLIN